Stifel Financial
TRIB

Stifel Financial’s Trinity Biotech TRIB Stock Holding History

Stifel Financial’s Portfolio TRIB Stock Details TRIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-3,308
Closed -$297K – 2367
2015
Q2 		$297K Buy
+3,308
New +$286K ﹤0.01% 1965

Other funds holding TRIB

Boston Partners
Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return
HA
Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
PIM
Paradice Investment Management Denver, Colorado $532M AUM 29.6% 1-Year Est. Return
AAM
ACK Asset Management Greenwich, Connecticut $801M AUM 60.42% 1-Year Est. Return
CCMLC
Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
SM
Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return

Stifel Financial's TRIB Position: Q3 2015 in Review

Stifel Financial sold out of Trinity Biotech (TRIB) in Q3 2015, closing a stake of 3,308 shares — an estimated $297K sold.

Stifel Financial first reported a position in TRIB in Q2 2015 and held it in 1 quarter. The position peaked at $297K in Q2 2015. 92 funds tracked by Wall St. Rank hold TRIB as of Q3 2015.

  • Stifel Financial reported no remaining Trinity Biotech position as of Q3 2015 after selling out during the quarter.
  • Stifel Financial sold 3,308 Trinity Biotech shares in Q3 2015, an estimated $297K.
  • Stifel Financial first reported a position in Trinity Biotech in Q2 2015 and held it in 1 quarter.
  • Stifel Financial's Trinity Biotech position peaked at $297K in Q2 2015.
  • 92 funds tracked by Wall St. Rank held Trinity Biotech as of Q3 2015.

Based on Stifel Financial's 13F filing for Q3 2015, filed 16 Nov 2015.